Human TLR9 siRNA purchased from Sigma (St. Louis, MO) and CCN1, Cav-1 siRNA from Santa Cruz Biotechnology (Santa Cruz, CA), Src siRNA from Origenes (Rockville, MD), JNK and BiP siRNA from Cell Signaling Technology (Danvers, MA) and INTERFERin® from Polyplus (Illkirch, FRANCE). Transfection procedure was performed per INTERFERin® manufacturer’s instruction.
Human CCN1 plasmid constructs were designed following pcDNA3.1/V5-His© TOPO® TA Expression Kit (Invitrogen, Grand Island, NY). CCN1 constructs were transfected using LipoD293 (SignaGen, Rockville, MD) and followed manufacturer’s instruction. Transfected CCN1 plasmids were detected using anti-V5 antibody (Invitrogen).
Human CCN1 plasmid constructs were designed following pcDNA3.1/V5-His© TOPO® TA Expression Kit (Invitrogen, Grand Island, NY). CCN1 constructs were transfected using LipoD293 (SignaGen, Rockville, MD) and followed manufacturer’s instruction. Transfected CCN1 plasmids were detected using anti-V5 antibody (Invitrogen).